Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial

Key Points

• Higher immune expression correlates with improved overall survival in metastatic CRC patients receiving anti-EGFR therapy.
• The analysis reveals significant differences in survival outcomes based on tumor region and treatment arm.
• Data were evaluated from patients undergoing maintenance therapy in the PanaMa trial with RAS wt metastatic CRC.
• The findings highlight the potential for the immune microenvironment to serve as a prognostic and predictive biomarker.